<DOC>
	<DOCNO>NCT00684710</DOCNO>
	<brief_summary>This study provide initial assessment safety , tolerability , pharmacokinetics ( PK ) PAZ-417 administration ascend single oral dos healthy young Japanese male healthy elderly Japanese male subject .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability Activity One Dose PAZ-417 Given Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria 1 . Men age 20 45 year inclusive ( healthy young male subject ) â‰¥65 year inclusive ( healthy elderly male subject ) 2 . Nonsmoker smoker few 10 cigarette per day . 3 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead electrocardiogram ( ECG ) . Exclusion Criteria 1 . Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 2 . Subjects identify risk hypercoagulability 3 . Use investigational prescription drug within 30 day test article administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Alzheimer Disease</keyword>
</DOC>